Comparative Pharmacology
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SIGNIFOR LAR KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SIGNIFOR LAR KIT.
LANREOTIDE ACETATE vs SIGNIFOR LAR KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lanreotide is a synthetic octapeptide analog of somatostatin. It binds predominantly to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. It also reduces secretion of gastrointestinal hormones such as serotonin and gastrin.
Somatostatin analog that binds to somatostatin receptors (primarily sst2 and sst5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, and reducing hormone release from neuroendocrine tumors.
90 mg subcutaneously every 4 weeks
Intramuscular injection: 40 mg every 28 days.
None Documented
None Documented
Terminal elimination half-life: 23-30 hours following subcutaneous administration; prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life following intramuscular injection of the long-acting formulation is approximately 19 days (range 15–23 days), supporting monthly dosing intervals.
Primarily renal (approximately 60-70% of dose excreted unchanged in urine), with biliary/fecal elimination accounting for about 30%.
Primarily renal (approximately 85% of administered dose excreted unchanged in urine); minimal biliary/fecal excretion (less than 10%).
Category C
Category C
Somatostatin Analog
Somatostatin Analog